(Q35912403)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

review article

1 reference

title

Replication-selective oncolytic viruses in the treatment of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

author name string

Henk G van der Poel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

publication date

1 February 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

3 January 2020

page(s)

141-161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15472714%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.cgt.7700771

3 January 2020

exact match

0 references

cites work

Apoptosis: an innate immune response to virus infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Regression of Burkitt's lymphoma in association with measles infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Studies on the use of viruses in the treatment of carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Present status of oncolytic virus studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Treatment of human cancer with mumps virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Leukaemia and neoplastic processes treated with Langat and Kyasanur Forest disease viruses: a clinical and laboratory study of 28 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

The preferential cytotoxicity of reovirus for certain transformed cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Lessons from hereditary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Reovirus oncolysis of human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Reovirus therapy of lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Newcastle disease virus (NDV): brief history of its oncolytic strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Antineoplasic activity of parvoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Cytolytic viruses as potential anti-cancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replicative oncolytic adenoviruses in multimodal cancer regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

A novel E1A-E1B mutant adenovirus induces glioma regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Oncolytic herpes simplex virus vectors for cancer virotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Intergeneric poliovirus recombinants for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Combined transcriptional and transductional targeting improves the specificity and efficacy of adenoviral gene delivery to ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replicating parvoviruses that target colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Enhancement of replication of genetically engineered herpes simplex viruses by ionizing radiation: a new paradigm for destruction of therapeutically intractable tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Ionizing radiation does not alter the antitumor activity of herpes simplex virus vector G207 in subcutaneous tumor models of human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

MTH-68/H oncolytic viral treatment in human high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

Regression of Hodgkin's disease after measles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Propagation of Newcastle disease virus in Ehrlich ascites cells in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Sensitization of transformed rat fibroblasts to killing by parvovirus minute virus of mice correlates with an increase in viral gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Transcriptional targeting of herpes simplex virus for cell-specific replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Adenovirus type 5 E4 open reading frame 4 protein induces apoptosis in transformed cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

Cytokine gene transfer enhances herpes oncolytic therapy in murine squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021

ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700771

7 January 2021